Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Pivotal Phase 3 Study of Iomab-B Prior to Allogeneic Hematopoietic Cell Transplant Versus Conventional Care in Older Subjects With Active, Relapsed or Refractory Acute Myeloid Leukemia (AML)

NCT02665065 is registered in ClinicalTrials.gov with Actinium Pharmaceuticals as lead sponsor.

NCT NCT02665065
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02665065 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Pivotal Phase 3 Study of Iomab-B Prior to Allogeneic Hematopoietic Cell Transplant Versus Conventional Care in Older Subjects With Active, Relapsed or Refractory Acute Myeloid Leukemia (AML)
Lead sponsor
Actinium Pharmaceuticals
Phase
Phase 3
Overall status
Active, not recruiting
Start date
June 30, 2016
Completion date
December 31, 2026
Enrollment
153 (actual)
Sites
24

Conditions

As the registry lists them; a condition with its own page is linked.

acute myelogenous leukemia, acute myeloid leukemia, aml, bone marrow transplant, leukemia, acute myelogenous, leukemia, acute myeloid, leukemia, myeloid, acute, myelogenous leukemia, acute, myeloid leukemia, acute